224 citations,
February 2013 in “The Journal of clinical investigation/The journal of clinical investigation” ERG increases SOX9, promoting prostate cancer growth and invasion.
2 citations,
June 2020 in “Research Square (Research Square)” A prostate cancer drug can lower the levels of a protein that the coronavirus uses to enter lung cells.
1 citations,
January 2021 in “Research Square (Research Square)” Enzalutamide, a prostate cancer drug, may help prevent COVID-19 by blocking the virus from entering lung cells.
123 citations,
May 2020 in “Drug Development Research” Men's sensitivity to male hormones might affect how severe COVID-19 gets for them.
4 citations,
March 2022 in “Journal of Infection” Anti-androgen therapy might help protect against COVID-19 infection and reduce death risk.
2 citations,
October 2020 in “Annals of Oncology” Men may be more vulnerable to severe COVID-19 due to genetic and hormonal factors, but more research is needed.
January 2021 in “International Journal of Dermatology” Possible link between COVID-19 and hair loss; more research needed.
80 citations,
June 2020 in “Dermatopathology” COVID-19 can cause various skin lesions, which may result from the virus and immune response, and are not directly linked to illness severity.
26 citations,
September 2020 in “Journal of the European Academy of Dermatology and Venereology” A certain genetic variant in the androgen receptor may predict the severity of COVID-19 in men.
June 2021 in “EBioMedicine” The authors maintain that shorter androgen receptor alleles may lead to milder COVID-19 by positively affecting the immune response, not due to changes in testosterone levels or activity.
January 2010 in “Yearbook of Endocrinology” Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.
71 citations,
April 2020 in “Journal of Cosmetic Dermatology” Genetic differences may affect COVID-19 deaths; anti-androgens could be potential treatment.
1 citations,
August 2021 in “Internal Medicine Journal” After severe COVID-19, 71% of patients experienced excessive hair shedding and thinning within 3 months due to factors like low oxygen levels, medication, stress, and autoimmune disease.
176 citations,
May 2020 in “Dermatologic Therapy” COVID-19 can cause different skin symptoms that may help with early diagnosis and show how severe the disease is.
36 citations,
July 2020 in “Frontiers in Medicine” Spironolactone might help protect against severe lung problems in COVID-19 patients.
12 citations,
August 2020 in “Annals of Oncology” Androgen deprivation therapy might be better for preventing COVID-19 than treating it.
6 citations,
September 2020 in “Journal of The American Academy of Dermatology” Severe male balding may increase the risk of serious COVID-19, and treatments that reduce androgens or block a specific enzyme might help protect these individuals.
January 2021 in “Journal of the European Academy of Dermatology and Venereology” PrEP doesn't increase STI risk in high-risk men, anti-androgen drugs may lower ICU admission for male COVID-19 patients, a 3-point injection is better for crow's feet, and the 'Geriatric-8' tool could help assess frailty in older skin cancer patients.
21 citations,
January 2021 in “Therapeutic Advances in Endocrinology and Metabolism” Testosterone may have a dual role in COVID-19, potentially worsening outcomes in men, and testosterone therapy could help some patients, but more research is needed.
December 2023 in “Tuberkuloz ve Toraks/Tüberküloz ve toraks” Many COVID-19 patients have long-term symptoms, especially women, but certain medications may help reduce these symptoms.
41 citations,
February 2021 in “Cureus” Proxalutamide helps COVID-19 patients get rid of the virus faster and recover quicker.
42 citations,
July 2021 in “Frontiers in Medicine” Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.
June 2023 in “BMC Pharmacology and Toxicology” The trial will test if proxalutamide is safe and effective in reducing death in severe COVID-19 patients.
1 citations,
January 2022 in “European Journal of Pharmacology” Riboflavin 5′-phosphate (FMN) shows potential for treating androgen-related conditions but may be limited in treating prostate cancer.
October 2020 in “Проблемы эндокринологии” Men with higher androgen levels may have severe COVID-19 symptoms, but those on antiandrogen therapy are less likely to contract the virus and have milder symptoms. Anti-androgen drugs could potentially treat COVID-19, but more research is needed.
134 citations,
April 2020 in “Journal of Cosmetic Dermatology” Male pattern hair loss could hint at androgens affecting COVID-19 severity.
49 citations,
January 2021 in “Journal of The European Academy of Dermatology and Venereology” Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.
36 citations,
November 2020 in “Journal of The European Academy of Dermatology and Venereology” 5-alpha-reductase inhibitors may reduce COVID-19 symptoms in bald males.
32 citations,
July 2020 in “Journal of The American Academy of Dermatology” AGA linked to worse COVID-19 outcomes in men.
5 citations,
May 2020 in “Dermatologic Therapy” 5-alpha reductase inhibitors might worsen lung recovery in COVID-19 patients, suggesting a pause in their use.